Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Phase I/II Study of Subretinal LX102 in Neovascular Age-related Macular Degeneration
CTR20230194Phase 2Active
- Sponsor
- Langxin Qisheng
- Start
- Feb 2023
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of LX102 in exudative macular degeneration, sponsored by Langxin Qisheng. Started Feb 2023; status: active.
02
Drugs
LX102
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20230194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230194.